ストックスクリーナーアプリを入手
1.15
5.74%
-0.07
アフターアワーズ：
1.14
-0.01
-0.87%
前日終値:
$1.22
開ける：
$1.25
24時間の取引高:
720.06K
Relative Volume:
0.40
時価総額：
$146.27M
収益：
$79.18M
当期純損益:
$-136.99M
株価収益率:
-1.0904
EPS:
-1.0547
ネットキャッシュフロー:
$-120.11M
1週間 パフォーマンス:
-14.81%
1か月 パフォーマンス:
+7.48%
6か月 パフォーマンス:
-68.14%
1年 パフォーマンス:
-64.40%
1日の値動き範囲:
$1.145
$1.26
1週間の範囲:
$1.145
$1.40
52週間の値動き範囲:
$0.7796
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Compare ADCT vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.15 | 146.27M | 79.18M | -136.99M | -120.11M | -1.0547 |
TAK
Takeda Pharmaceutical Co Adr
|
17.24 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.78 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.81 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.35 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
528.47 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 開始されました | Guggenheim | Buy |
| 2023-08-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-04-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 開始されました | CapitalOne | Overweight |
| 2022-11-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-08-17 | 再開されました | Jefferies | Buy |
| 2021-08-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-06-09 | 開始されました | BofA/Merrill | Buy |
| 2020-06-09 | 開始されました | Cowen | Outperform |
すべてを表示
Adc Therapeutics Sa (ADCT) 最新ニュース
ADCT|ADC Therapeutics SA|Price:1.150|Chg%:-0.045 - TradingKey
TradingKey - TradingKey
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Finan - GuruFocus
ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation - AD HOC NEWS
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops - AD HOC NEWS
ADC Therapeutics (NYSE:ADCT) Shares Down 6.3%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeut - The National Law Review
ADC Therapeutics (ADCT) Holds Near Support Amid Slight Decline – Technical AnalysisVWAP Breakout - dars.gov.et
Press Release: ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - Moomoo
Biocytogen and Whitehawk partner to develop ADCs - Pharmaceutical Technology
The ZYNLONTA therapy. ADCT targets US lymphoma patients with a focused antibody-drug treatment - ad-hoc-news.de
Novartis finally enters the ADC field with an unprecedented technology - Agefi.com
ADC Therapeutics Grants One-Time Retention Awards to Executives - TipRanks
ADC Therapeutics (ADCT) CMO awarded 213,900 RSUs, raising holdings to 896,317 shares - Stock Titan
ADC Therapeutics (ADCT) grants 221,100 RSUs to Chief Legal Officer - Stock Titan
ADC Therapeutics (ADCT) grants CFO 203,700 RSUs as equity award - Stock Titan
ADC Therapeutics (ADCT) CEO receives 675,000 RSU equity award in Form 4 filing - Stock Titan
Executive retention awards approved at ADC Therapeutics (NYSE: ADCT) - Stock Titan
ADC Therapeutics Announces New Employee Inducement Grant - AOL.com
ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL - BioPharm International
ADC Therapeutics completes LOTIS-7 trial enrollment - grafa.com
ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study - marketscreener.com
ADC Therapeutics completes enrollment in LOTIS-7 trial - Investing.com
ADC Therapeutics completes enrollment in LOTIS-7 trial By Investing.com - Investing.com Nigeria
ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma - Stock Titan
ADC Therapeutics updates trial strategy, shares react to oncology shift - ad-hoc-news.de
ETFs Investing in ADC Therapeutics Ltd Stocks - TradingView
ADC Therapeutics SA(NYSE: ADCT) added to Russell 2000 Value Benchmark - marketscreener.com
ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index - marketscreener.com
ADCT stock plunges on safety concerns despite positive lymphoma data - MSN
ADC Therapeutics SA(NYSE: ADCT) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
ADCT Q3 2020 Earnings Call - BigGo ファイナンス
ADC Therapeutics SA(NYSE: ADCT) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to revenue forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views - Yahoo Finance
Enterprise value to EBIT forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
Enterprise value to EBITDA forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
Price to earnings forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
ADCT News | ADC THERAPEUTICS SA (NYSE:ADCT) - ChartMill
Price to sales forward of ADC Therapeutics SA – NYSE:ADCT - TradingView
ADC Therapeutics Ltd Actuals & Estimates (NYSE:ADCT) - TradingView
ADCT Forecast — Price Target — Prediction for 2027 - TradingView
ADC Therapeutics Announces ZYNLONTA-Focused Strategic Reorganization - The Globe and Mail
ADC Therapeutics launches restructuring around ZYNLONTA - grafa.com
ADC Therapeutics Announces 17% Workforce Reduction and Strategic Reorganization to Boost ZYNLONTA® Growth and Regulatory Milestones - Minichart
Bronstein, Gewirtz & Grossman, LLC (ADCT) Investigation: Bronstei - The National Law Review
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details - Stocktwits
Adc Therapeutics Sa (ADCT) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
0.52%
大文字化:
|
ボリューム (24 時間):